Get the Stockscreener App
38.79
16.13%
-7.46
After Hours:
38.63
-0.16
-0.41%
Lenz Therapeutics Inc stock is traded at $38.79, with a volume of 3.92M.
It is down -16.13% in the last 24 hours and down -7.00% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$46.25
Open:
$46.75
24h Volume:
3.92M
Relative Volume:
6.72
Market Cap:
$1.11B
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-6.9301
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-20.41%
1M Performance:
-7.00%
6M Performance:
+109.22%
1Y Performance:
+64.36%
1-Day Range:
$38.43
$46.75
1-Week Range:
$38.43
$49.25
52-Week Range:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
38.79 | 1.40B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
When is the best time to exit LENZ Therapeutics Inc.Market Movers & Verified Technical Signals - newser.com
Using portfolio simulators with LENZ Therapeutics Inc. includedWeekly Trend Report & AI Powered Market Entry Ideas - newser.com
Will a bounce in LENZ Therapeutics Inc. offer an exitPortfolio Value Summary & Accurate Trade Setup Notifications - newser.com
Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch - Investing.com India
Weiss Ratings Reiterates Sell (D-) Rating for LENZ Therapeutics (NASDAQ:LENZ) - MarketBeat
Visual analytics tools that track LENZ Therapeutics Inc. performance2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Forecasting LENZ Therapeutics Inc. price range with options dataSell Signal & High Yield Stock Recommendations - newser.com
Lenz Therapeutics sells $80 million in common stock in block trade By Investing.com - Investing.com Australia
Lenz Therapeutics sells $80 million in common stock in block trade - Investing.com India
Lenz Therapeutics Announces U.S. Availability of VIZZ Eye Drops for Presbyopia - VisionMonday.com
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 3.9%Here's Why - MarketBeat
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, L - PharmiWeb.com
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, Lenz Therapeutics, Orasis Pharmaceuticals, and Tenpoint TherapeuticsResearchAndMarkets.com | FinancialContent - FinancialContent
Is LENZ Therapeutics Inc. forming a bottoming base2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Smart tools for monitoring LENZ Therapeutics Inc.’s price actionMarket Growth Review & AI Driven Price Forecasts - newser.com
Is LENZ Therapeutics Inc. stock affected by interest rate hikesPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com
LENZ Therapeutics’s Valuation: Examining the Impact of VIZZ’s Groundbreaking FDA Approval and US Launch - Sahm
What analysts say about LENZ Therapeutics Inc stockOptions Trading Strategies & Small Investment Portfolio Growth - earlytimes.in
Chart based analysis of LENZ Therapeutics Inc. trendsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - newser.com
Using economic indicators to assess LENZ Therapeutics Inc. potential2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
TD Cowen Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LENZ Therapeutics(LENZ.US) 10% Shareholder Sells US$10.35 Million in Common Stock - 富途牛牛
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Will LENZ Therapeutics Inc. stock split attract more investorsMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
Vizz Eyedrops Now Available to Improve Near Vision in Adults - Ophthalmology Advisor
VIZZ presbyopia eye drops launch in the US - Eyes On Eyecare
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Invest In Growth - Yahoo Finance
LENZ launches VIZZ eye drops for presbyopia treatment in US By Investing.com - Investing.com Nigeria
LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States - InvisionMag.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - 富途牛牛
LENZ Therapeutics Announces Commercial Product Availability of V - GuruFocus
LENZ Therapeutics Says VIZZ 1.44% Presbyopia Eye Drops Available in US - MarketScreener
LENZ launches VIZZ eye drops for presbyopia treatment in US - Investing.com India
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - WV News
93% Success Rate: LENZ Therapeutics Launches Revolutionary 10-Hour Eye Drops for 128M Adults with Presbyopia - Stock Titan
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
What drives LENZ Therapeutics Inc stock priceVolatility Trading Techniques & Superior Capital Trading Plans - earlytimes.in
Lenz Therapeutics stock hits 52-week high at 44.03 USD By Investing.com - Investing.com Nigeria
Is LENZ Therapeutics Inc a good long term investmentVWAP Trading Strategies & Consistent Double Returns - earlytimes.in
LENZ Therapeutics (NASDAQ:LENZ) Hits New 12-Month HighHere's What Happened - MarketBeat
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Sep 30 '25 |
Sale |
46.01 |
92,030 |
4,234,695 |
764,127 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
90,654 |
3,828,632 |
1,183,543 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
44,650 |
1,885,724 |
856,157 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
52,419 |
2,072,738 |
1,321,640 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
47,443 |
1,850,891 |
1,274,197 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
26,161 |
1,050,392 |
1,374,059 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
25,818 |
1,020,888 |
924,175 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
23,368 |
911,655 |
900,807 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
12,885 |
517,356 |
949,993 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
145,051 |
5,729,514 |
1,430,848 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):